Slide 1: Earnings Call Q4 & Annual 2025
March 05, 2026 EARNINGS CALL Q4 & ANNUAL 2025 OFER HAVIV | PRESIDENT & CEO
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding o
Slide 3: Earnings Call Q4 2025 Agenda
Earnings Call Q4 2025 AGENDA By Ofer Haviv CEO Update By Yaron Eldad CFO Update Q&A
Slide 4: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERSREAL-WORLD INNOVATION Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries 4
Slide 5: Gen AI Engine: ChemPass AI
GEN AI ENGINE Growing number of collaborations for diverse drug targets Strategic collaborations for ag-chemical development with proven results PIONEERING IN PHARMA REVOLUTIONIZING AG OUR STORY ChemPass AI™ - computational engine for the design & optimization of small molecules
Slide 6: Introducing ChemPass AI: Breaking Chemical Space Limitation
NOVELTY - VAST CHEMICAL TERRITORIES based on a 38B-molecule chemical library, the engine designs novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities INTRODUCING CHEMPASS AI™: BREAKING CHEMICAL SPACE LIMITATION & MULTI-PARAMET
Slide 7: Technological Collaborations with Google Cloud
7 Technological Collaborations with GOOGLE CLOUDfrom generative models to autonomous discovery First Collaboration – FIRST-IN-CLASS FOUNDATION MODEL Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion m
Slide 8: Evogene's Unique Offering – Proprietary Molecular Design
Potency (Binding Affinity) Selectivity ML Models (QSAR) Scaffold Solubility Lipophilicity (LogP) Molecular Weight Hydrogen Bond Donors/Acceptors Chemical Stability Metabolic Stability Synthetic Accessibility IP/Novelty EVOGENE’S UNIQUE OFFERING – PROPRIETARY MOLECULAR DESIGN 8 A POWERFUL COMBINATION
Slide 9: Capturing the Value of ChemPass AI – Our Business Model
Literature search, data preprocessing and target modeling Target elucidation and biological interpretation HITSCREENING TARGETPREPROCESSING HIT-TO-LEAD Purchase hits and test activity and selectivity Synthesis of novel leads and validation Identify potential hits using PointHit Identify elaborated a
Slide 10: Evogene - Real-World Innovation: Pharma and Ag Divisions
10 PHARMA DIVISION – Drugs EXTERNAL COLLABORATIONS Neutrophil-Derived Inflammatory Diseases Demyelination Disorders Lung Cancer Metabolic Disease EXTERNAL COLLABORATIONS Herbicides Herbicides INTERNAL PIPELINE Wheat Blotch EVOGENE - REAL-WORLD INNOVATION AG DIVISION* – Ag-Chemicals AG DIVISION* – Op
Slide 11: Generating Real-World Innovation
11 High-potency molecules AI-first designed molecules optimized through targeted experimental validation Novel Chemical Space & IP Based on a 38B-molecule chemical library, the platform designs active novel compounds We design highly potent and novel small molecules, optimized across multiple-parame
Slide 12: Earnings Call 2025 Agenda
EARNINGS CALL 04 2025 AGENDA CEO UPDATE - By Ofer Haviv CFO UPDATE - By Yaron Eldad Q&A n evOgene
Slide 13: Evogene Subsidiaries' Activity
13 EVOGENE SUBSIDIARIES’ ACTIVITY
Slide 14: CFO Update Financial Highlights
CFO UPDATE Financial Highlights CFO UPDATE Financial Highlights
Slide 15: CFO Update Financial Highlights
CFO UPDATE Financial Highlights
Slide 16: Consolidated Statements of Profit or Loss
CONSOLIDATED STATEMENTS OF PROFIT ORLOSS C Fi 0 U Pp DATE U,S. dollars in thousands (except share and per share amounts) FINANCIAL HIGHLIGHTS ES - 2026) Revenues $3853 $5577 $ 318 8 1,583 Cost of Revenues Inventory impairment 2180 - 2,180 - Other cost of revenues 1914 2380 104 692 Total Cost of Reve
Slide 17: Earnings Call Q3 2025 Agenda
Earnings Call Q3 2025 AGENDA By Ofer Haviv CEO Update By Yaron Eldad CFO Update Q&A
Slide 18: Creating Real-World Innovation for a Better Future
Creating REAL-WORLD INNOVATION for a better future evOgene *